E
Evommune, Inc. (EVMN)
NYQ – Real vaqt narxi. Valyuta: USD
22.69
-0.52 (-2.24%)
Yopilishda: May 12, 2026, 4:00 PM EDT
23.00
+0.31 (1.37%)
Bozor oldidan: May 13, 2026, 7:32 AM EDT
Find any stock by ticker or company name

NYQ – Real vaqt narxi. Valyuta: USD
22.69
-0.52 (-2.24%)
Yopilishda: May 12, 2026, 4:00 PM EDT
23.00
+0.31 (1.37%)
Bozor oldidan: May 13, 2026, 7:32 AM EDT
Evommune, Inc. Amerika Qo'shma Shtatlarida klinik bosqichdagi biotexnologiya kompaniyasi sifatida faoliyat yuritadi. Kompaniya surunkali yallig'lanish kasalliklarining asosiy omillariga qaratilgan terapiyalarni ishlab chiqadi, dastlabki klinik rivojlanish dasturlari surunkali spontan ürtiker, atopik dermatit va yarali kolitga qaratilgan. Uning mahsulotlari orasida CSU va ADni davolash uchun EVO756; va AD va UCni davolash uchun EVO301 mavjud. Kompaniya 2020 yilda tashkil etilgan va Palo Alto, Kaliforniyada joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Daniel J. Burge M.d. | Senior Vice President of Clinical Development |
| Dr. Eugene Andrew Bauer M.D. | Co-Founder, Chief Medical Officer & Director |
| Dr. Jeegar Patel Ph.D. | Chief Scientific Officer |
| Dr. Lou Sehl Ph.D. | Senior Vice President of Technical Operations |
| Mr. Gregory S. Moss Esq. | Chief Business & Legal Officer, Corporate Secretary and Chief Compliance Officer |
| Mr. J. Mark Jackson M.D. |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-07 | 10-Q | evmn-20260331.htm |
| 2026-04-21 | ARS | evmn-2026-proxy-ars.pdf |
| 2026-04-17 | S-1 | d127341ds1.htm |
| 2026-04-13 | 8-K | evmn-20260413.htm |
| 2026-03-05 | 10-K | evmn-20251231.htm |
| 2026-02-13 | 8-K | evmn-20260212.htm |
| 2026-02-10 | 8-K | evmn-20260210.htm |
| 2025-12-11 | 10-Q | evmn-20250930.htm |
| 2025-11-07 | S-8 | d78726ds8.htm |
| 2025-11-07 | 8-K | d38367d8k.htm |
| Senior Vice President of Clinical Development |
| Mr. Kyle Carver CPA, M.B.A. | Chief Financial Officer |
| Mr. Luis C. Pena | Founder, President, CEO & Director |
| Ms. Janice Drew M.P.H. | Chief of Development Operations |